RxDoctor Payments Data

Amy Hussey, DO

Family Medicine · Fort Worth, TXNPI 1861755506

Payments from drug & device makers

$4,433in general payments, 2019–2025

Across 237 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$758
  • AbbVie$568
  • Lilly USA, LLC$498
  • AstraZeneca$402
  • Astellas Pharma US Inc$323
  • Boehringer Ingelheim$258
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$4,433100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,433 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$51,468
Medicare patients
166
Services billed
796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$107,540
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$24,799
JardianceEmpagliflozin25$23,543
FarxigaDapagliflozin Propanediol21$23,258
EliquisApixaban13$16,312
MounjaroTirzepatide12$13,182
SymbicortBudesonide/Formoterol Fumarate17$8,163
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,057
Atorvastatin Calcium160$1,552
Albuterol Sulfate HfaAlbuterol Sulfate59$1,241
Rosuvastatin Calcium90$1,192
Levothyroxine Sodium82$824
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen27$824
Metoprolol Succinate54$823
Pregabalin26$708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$758$107,54086 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$402$56,22070 claims
Boehringer IngelheimJardiance$258$23,54325 claims
PfizerEliquis$171$16,31213 claims
Lilly USA, LLCMounjaro$498$13,18212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →